PMCB Past Earnings image   This PMCB past earnings page last updated 9/19/2022
PMCB Past Earnings
PeriodPast Earnings DateGAAP
Q1 20239/14/2022-0.070
Q4 20227/28/2022-0.060
Q3 20223/15/2022-0.040
Q2 202212/14/2021-0.060
Q1 20229/14/2021-0.640
PMCB Past Revenue
PeriodPast Earnings DateGAAP
Q1 20239/14/2022NA
Q4 20227/28/2022NA
Q3 20223/15/2022NA
Q2 202212/14/2021NA
Q1 20229/14/2021NA
Quotes delayed 20 minutes

Email EnvelopeFree PMCB Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
PharmaCyte Biotech (PMCB) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

PMD Past Earnings
PMVP Past Earnings
POAI Past Earnings
PODD Past Earnings
PRAH Past Earnings
PRAX Past Earnings
PRCT Past Earnings
PRGO Past Earnings
PRLD Past Earnings
PROG Past Earnings

PMCB Past Earnings Q&A

What was the best and worst PMCB past earnings results?
For PharmaCyte Biotech, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest PMCB past earnings result in our data set was -0.040/share posted in Q3 2022, while the lowest was in Q1 2022 when PMCB posted -0.640/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q1 2023 when PMCB reported NA in revenue, while the quarter with the lowest revenue in our data set was Q1 2023 at NA of revenue.

  Suggested answer: There are 5 PMCB past earnings results in our data set.

On this page we presented the PMCB past earnings date information for PharmaCyte Biotech. Reviewing that PMCB Past Earnings for the company, we see that the highest past earnings result in our data set was in Q3 2022, when PMCB posted gaap of -0.040/share. Meanwhile the lowest PMCB past earnings result was in Q1 2022, when PMCB posted gaap of -0.640/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q1 2023 when PMCB reported NA in revenue, while the smallest revenue quarter was Q1 2023 when PMCB reported NA in revenue.

Any self directed investor doing their due diligence on PMCB or any other given stock can benefit from researching all of the PharmaCyte Biotech past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you to make it easy for investors to investigate PharmaCyte Biotech past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for PMCB. Thanks for visiting, and the next time you need to research PMCB past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: POM Historical Stock Prices, FSDC YTD Return, AMGN Insider Buying.


PMCB Past Earnings | | Copyright © 2020 - 2022, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.